Genomic DNA of hematopoietic stem and progenitor cells (HSPC genomic DNA)

The genomic DNA of hematopoietic stem and progenitor cells (HSPCs) serves as the comprehensive genetic blueprint for the development and maintenance of the entire blood and immune systems [5]. In modern medicine, this genomic DNA is a primary therapeutic target for ex vivo gene therapies and gene-editing interventions designed to treat severe genetic disorders such as sickle cell disease, beta-thalassemia, and various primary immunodeficiencies [1, 2]. By utilizing technologies like CRISPR/Cas9 or lentiviral vectors, clinicians can precisely modify the DNA within a patient's own CD34+ cells to either disrupt disease-causing elements or insert functional gene sequences [2, 3]. These modified cells are then re-infused into the patient, where they engraft in the bone marrow and produce a continuous supply of healthy, functional progeny [1, 4]. The therapeutic success of targeting HSPC DNA depends on achieving high levels of stable modification while minimizing risks such as off-target effects or insertional mutagenesis, which could lead to hematologic malignancies [6]. As such, the HSPC genome represents a critical substrate for curative strategies in regenerative medicine, transforming the treatment landscape for inherited hematologic conditions [1].

Other names

HSPC DNAHematopoietic stem cell genomeCD34+ cell genomic DNAHSPC genome

Modification of the genomic sequence via site-specific gene editing (e.g., CRISPR/Cas9) or stable gene addition using viral vectors (e.g., lentivirus) to restore or alter cellular function [1, 2, 3].